The burden of multiresistant bacteria in German intensive care units.

in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008; 121: 689–96. 3. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165–74. 4. Bonacorsi S, Clermont O, Houdouin V et al. Molecular analysis and experimental virulence of French and North American Escherichia coli neonatal meningitis isolates: identification of a new virulent clone. J Infect Dis 2003; 187: 1895–906. 5. Eckert C, Gautier V, Saladin-Allard M et al. Dissemination of CTX-M-type b-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48: 1249–55. 6. Ramdani-Bouguessa N, Mendonça N, Leitao J et al. CTX-M-3 and CTX-M-15 extended-spectrum b-lactamases in isolates of Escherichia coli from a hospital in Algiers, Algeria. J Clin Microbiol 2006; 44: 4584–6. 7. Pitout JD, Nordmann P, Laupland KB et al. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52–9. 8. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Microbiol 2006; 18: 64–70.